3Nielsen OS,Munro AJ,Tannock IF. Bone metastases:pathophysiology and management policy[J].Journal of Clinical Oncology,1991,(03):509-524.
4蒋宁一.肿瘤核医学[M]北京:人民卫生出版社,2002437-452.
5Sheffield DP,Biles PB,Orom HB. Raceand sex differences in cutaneous pain perception[J].Psychosomatic Medicine,2000,(04):517-523.
6Tian JH,Zhang JM,Hou QT. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonam as a palliative treatment for painful skeletal metastases in China[J].European Journal of Nuclear Medicine,1999,(01):2-7.doi:10.1007/s002590050351.
7Seraflni AN,Houston SJ,Resche I. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a doudle-blind placebo-controlled clinical trial[J].Journal of Clinical Oncology,1998,(04):1574-1581.
8Cameron PJ,Klemp PF,Martindale AA. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy[J].Nuclear Medicine Communications,1999,(07):609-615.doi:10.1097/00006231-199907000-00003.
9Serafini AD. Samarium 153Sm-lexidronan for the palliation of bone pain associated with metastases[J].Cancer,2000,(12):2934-2939.doi:10.1002/1097-0142(20000615)88:12+<2934::AID-CNCR9>3.0.CO;2-S.
10Anderson PM,Wiseman GA,Dispenzieri A. High-dose salnarium-153 ethylene diamine tetramethylene phosphonate:low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases[J].Journal of Clinical Oncology,2002,(07):189-196.doi:10.1200/JCO.20.1.189.
